Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.

Solange PetersRolf StahelLukas BubendorfPhilip BonomiAugusto VillegasDariusz M KowalskiChristina S BaikDolores IslaJavier De Castro CarpenoPilar Garrido LopezAchim RittmeyerMarcello TiseoChristoph MeyenbergSanne de HaasLisa H LamMichael W LuThomas E Stinchcombe

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

T-DM1 showed a signal of activity in patients with HER2-overexpressing (IHC 3+) advanced NSCLC. Additional investigation into HER2 pathway alterations is needed to refine the target population for T-DM1 in NSCLC; however, HER2 IHC as a single parameter was an insufficient predictive biomarker.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
metastatic breast cancer
glycemic control
epidermal growth factor receptor
squamous cell carcinoma
brain metastases
positive breast cancer
adipose tissue
insulin resistance